Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report.

In response to public pressure to allow the medical use of marijuana, the Office of National Drug Control Policy, Washington, DC, funded a study by the Institute of Medicine evaluating the scientific evidence for benefits and risks of using marijuana as a medicine. The report used scientific reviews, public hearings, and reports from other agencies, and was evaluated by knowledgeable advisors and reviewers. It called for heavier investment in research on the biology of cannabinoid systems, careful clinical studies of cannabinoids in clinical syndromes, analysis of cannabinoids' psychological effects on symptoms, and evaluations of the health consequences of heavy marijuana use; recommends against the use of smoked marijuana in medicine and for the development of a medical cannabinoid inhaler; and recommends that compassionate use of marijuana be considered under carefully reviewed protocols. Finally, the report evaluates the abuse potential, tolerance, withdrawal, and gateway risks of medical use of cannabinoid drugs.

[1]  M. Roth,et al.  Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. , 1997, Chest.

[2]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[3]  T. Crowley,et al.  Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. , 1998, Drug and alcohol dependence.

[4]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[5]  Ac Moffat,et al.  Therapeutic uses of cannabis , 1997 .

[6]  J. Drazen,et al.  Inflammation and airway function in asthma: what you see is not necessarily what you get. , 1998, American journal of respiratory and critical care medicine.

[7]  J. Walker,et al.  Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. , 1996, European journal of pharmacology.

[8]  Ronald C. Kessler,et al.  Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. , 1994 .

[9]  C. Breivogel,et al.  Cannabis and endogenous cannabinoid systems. , 1998, Drug and alcohol dependence.

[10]  M. Roth,et al.  Airway inflammation in young marijuana and tobacco smokers. , 1998, American journal of respiratory and critical care medicine.

[11]  S. Watson,et al.  Marijuana and Medicine: Assessing the Science Base , 1999 .

[12]  M. Glass,et al.  Cannabinoid receptors and their endogenous agonists. , 1998, Annual review of pharmacology and toxicology.

[13]  N. Benowitz,et al.  CLINICAL STUDIES OF CANNABIS TOLERANCE AND DEPENDENCE * , 1976, Annals of the New York Academy of Sciences.

[14]  D. Tashkin.  Effects of Marijuana on the Lung and its Defenses against Infection and Cancer , 1999 .

[15]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[16]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[17]  Richard W. Foltin,et al.  Abstinence symptoms following smoked marijuana in humans , 1999, Psychopharmacology.

[18]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.